騰訊Q1研發投入同比增36% 持續投入夯實“向實”底座
格隆匯5月18日丨騰訊發佈2022年第一季度業績報吿,實現營業收入1354.71億元,淨利潤255.45億元,同比下降23%,Q1研發投入同比增長36%,達到153.83億元。儘管面臨互聯網行業結構性調整挑戰,但騰訊依然持續投入,研發費用連續五個季度同比增長超25%。
過去3年,騰訊在研發投入上已經累計投入超1366億元,建立起包括服務器、操作系統、芯片、SaaS等在內的完整自研體系,為服務實體經濟打下堅實基礎。截至2022年4月,騰訊在全球主要國家和地區專利申請公開總數超過5.6萬件,專利授權數量超過2.6萬件,其中,發明專利佔比超過90%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.